← Back to Clinical Trials
Recruiting NCT04984473

NCT04984473 A Study to Evaluate Breathing Muscle Training in Cardiac Rehab

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04984473
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Healthy
Study Type INTERVENTIONAL
Enrollment 42 participants
Start Date 2021-06-01
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Inspiratory muscle training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 42 participants in total. It began in 2021-06-01 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to understand if breathing muscle training combined with cardiac rehabilitation influences the blood flow and blood pressure response during exercise.

Eligibility Criteria

Inclusion Criteria - Heart Failure Group: * Adult 18 years and older. * English speaking. * Has a qualifying heart failure indication for center-based cardiac rehabilitation. Inclusion Criteria - Healthy Control Group: * Adult 18 years and older. * English speaking. * Absence of pulmonary, cardiovascular, musculoskeletal, neurologic, or orthopedic diseases. Controls will be matched for age and sex. Exclusion Criteria: * HF patients who are unable to engage in a regularly structured exercise training program as part of a clinically indicated center-based outpatient cardiac rehabilitation program. * Participants unable/unwilling to provide informed consent. * Uremia, history of allergy to iodides. Impaired renal function. * Creatinine value greater than 1.3 mg/dL (via clinical record within the past 6 months). * Diagnosis of liver disease.

Contact & Investigator

Central Contact

Eric Bruhn, MA

✉ bruhn.eric@mayo.edu

📞 507-266-2690

Principal Investigator

Joshua Smith, PhD

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT04984473 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04984473 currently recruiting?

Yes, NCT04984473 is actively recruiting participants. Contact the research team at bruhn.eric@mayo.edu for enrollment information.

Where is the NCT04984473 trial being conducted?

This trial is being conducted at Rochester, United States.

Who is sponsoring the NCT04984473 clinical trial?

NCT04984473 is sponsored by Mayo Clinic. The principal investigator is Joshua Smith, PhD at Mayo Clinic. The trial plans to enroll 42 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology